GeoffreyScottGilmartinMD

Pulmonology • Boston, MA

Critical Care Medicine, Pleural Disease

Attending Physician, Beth Israel Deaconess Medical Center Boston, MA Chief Development Officer Proteostasis Therapeutics Cambridge, MA

Join to view full profile

Dr. Gilmartin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gilmartin's full profile

Already have an account?

Office
330 Brookline Ave
GZ402
Boston, MA 02215
Phone+1 617-667-4120

Fax+1 617-667-1604

Education & Training

Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2004
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
The Warren Alpert Medical School of Brown UniversityClass of 1997

Certifications & Licensure

MA State Medical License 1999 - 2026

Publications & Presentations

PubMed

855 citations
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomi...
J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta
Lancet. 2016-10-29
775 citations
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a rand...
Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F. Weinstein
Lancet. 2016-10-29
44 citations
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States
Jennifer L. Taylor-Cousar, Minoo Niknian, Geoffrey Gilmartin, Joseph M. Pilewski
Journal of Cystic Fibrosis. 2016-01-01

Press Mentions

Summary of Parent Organized NPS Zoom PanelAugust 8th, 2020
Organoid-Based Personalized Medicine Trial Enrollment CompleteFebruary 28th, 2020
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic FibrosisFebruary 24th, 2020
Join now to see all